Digital health incubator Rock Health hosted the 2012 Health Innovation Summit last week in San Francisco. In a series of posts, I’ll be profiling some of the interesting new health companies represented at the summit. You can browse all of the startups I liked from the Rock Health summit here.
Hospital discharge papers aren’t enough to help patients recover from surgery at home and prevent high hospital readmission rates. So argues Pipette, a new digital health company designing a remote health-monitoring platform that allows payers and providers to track a patient’s recovery after leaving the hospital.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Compatible with smartphones, SMS-enabled cell phones, tablets and computers, Pipette asks discharged patients to input how they’re feeling throughout the day. It also checks in with them with reminders and tips, offers them resources for more information and has built-in capabilities that encourage good behaviors and discourage bad ones.
Cofounder Ryan Panchadsaram said the platform could cut healthcare costs by reducing the hospital readmission rate and allowing patients to be monitored from home using devices they already have, rather than being sent home with separate devices. It’s currently being piloted at two U.S. institutions.
See some of the features of the platform in this video from the Health Innovation Summit hosted by Rock Health, which graduated Pipette from its inaugural class last year.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
(Photo from http://blog.usepipette.com)
